We imagine that Biogen inventory (NASDAQ: BIIB), a biotechnology firm targeted on remedies for neur
We imagine that Biogen inventory (NASDAQ: BIIB), a biotechnology firm targeted on remedies for neurological illnesses, is an efficient shopping for alternative this present day. BIIB inventory trades close to $250 at present and it’s, in reality, down 27% from its pre-Covid excessive of round $340 in February 2020 – simply earlier than the coronavirus pandemic hit the world. BIIB inventory has had a risky experience the previous few months. It rallied from ranges of underneath $270 in March, when broader markets made the underside, to ranges north of $340 by finish of April. Since then the inventory has trended downward again to ranges of $240 by the top of October. The decline can partly be attributed to the corporate’s announcement of a delay in submitting for U.S. regulatory approval of Aducanumab in treating Alzheimer’s illness. One other issue that weighed on the inventory worth was Roche’s Evrysdi (risdiplam) approval by the U.S. FDA for the therapy of spinal muscular atrophy (SMA). Biogen’s Spinraza has been a blockbuster drug for the therapy for SMA with gross sales rising from underneath $900 million in 2017 to north of $2.Zero billion in 2019. Now with Roche’s Evrysdi approval, Spinraza will face stiff competitors.
The approval of Aducanumab will probably outline the longer term income and earnings progress for Biogen. Aducanumab’s peak gross sales, as an illustration, are touted to be as excessive as $12 billion. For perspective, Biogen’s whole gross sales in 2019 had been $14 billion. Because of this the inventory surged a whopping 44% in a single buying and selling session in early November this yr when the FDA issued constructive commentary across the drug. The FDA choice is predicted to be launched by March 2021, and BIIB inventory will probably see a robust uptick if the choice is in Biogen’s favor. BIIB inventory can provide greater than 35% upside if it recovers to pre-Covid ranges. On this observe we give attention to comparative evaluation of Biogen inventory efficiency throughout the present monetary disaster with that throughout the 2008 recession in our interactive dashboard.
2020 Coronavirus Disaster
Timeline of 2020 Disaster So Far:
- 12/12/2019: Coronavirus instances first reported in China
- 1/31/2020: WHO declares a worldwide well being emergency.
- 2/19/2020: Indicators of efficient containment in China and hopes of financial easing by main central banks helps S&P 500 attain a report excessive
- 3/23/2020: S&P 500 drops 34% from the height degree seen on Feb 19, as COVID-19 instances speed up exterior China. Doesn’t assist that oil costs crash in mid-March amid Saudi-led worth conflict
- Since 3/24/2020: S&P 500 recovers 66% from the lows seen on Mar 23, because the Fed’s multi-billion greenback stimulus bundle suppresses near-term survival nervousness and infuses liquidity into the system.
In distinction, right here is how BIIB inventory and the broader market fared throughout the 2007-08 disaster
Timeline of 2007-08 Disaster
- 10/1/2007: Approximate pre-crisis peak in S&P 500 index
- 9/1/2008 – 10/1/2008: Accelerated market decline equivalent to Lehman chapter submitting (9/15/08)
- 3/1/2009: Approximate bottoming out of S&P 500 index
- 12/31/2009: Preliminary restoration to ranges earlier than accelerated decline (round 9/1/2008)
BIIB and S&P 500 Efficiency Over 2007-08 Monetary Disaster
BIIB inventory declined from ranges of about $63 in October 2007 (pre-crisis peak) to ranges of $42 in March 2009 (because the markets bottomed out), implying BIIB inventory misplaced 32%. It staged a partial restoration publish the 2008 disaster, rallying 16% to ranges of $49 by January 2010. As compared, the S&P 500 Index noticed a decline of 51% from its peak in October 2007 and to its backside in March 2009, adopted by a pointy restoration of 48% by January 2010.
Biogen Fundamentals Over Current Years Have Been Strong
Biogen’s revenues elevated from $11.Four billion in 2016 to $14.Four billion in 2019, led by robust progress for Spinraza. The corporate has additionally seen its Internet Margins develop from 32% to 40% on a GAAP foundation, aiding its EPS, which grew from $16.96 to $31.47 over the identical interval. Extra just lately, Biogen garnered $10.6 billion in whole income, reflecting a 1.0% decline y-o-y within the first Three quarters of 2020, given the impression of the pandemic on whole affected person quantity. Wanting on the backside line, the corporate reported adjusted EPS of $22.29, reflecting 5% y-o-y decline, resulting from larger working prices within the pandemic.
Does Biogen Have Adequate Money Cushion To Meet Its Obligations By means of The Coronavirus Disaster?
Biogen whole debt elevated from $6.5 billion in 2016 to $7.Four billion on the finish of Q3 2020, whereas its whole money decreased from $7.7 billion to $3.6 billion over the identical interval. Biogen generated $4.6 billion money from operations within the first 9 months of 2020. The corporate has robust liquidity place to climate the present disaster.
Conclusion
Phases of Covid-19 Disaster:
- Early- to mid-March 2020: Concern of the coronavirus outbreak spreading quickly interprets into actuality, with the variety of instances accelerating globally
- Late-March 2020 onward: Social distancing measures + lockdowns
- April 2020: Fed stimulus suppresses near-term survival nervousness
- Might-June 2020: Restoration of demand, with gradual lifting of lockdowns – no panic anymore regardless of a gentle improve within the variety of instances
- July-October 2020: After poor Q2 outcomes, Q3 expectations had been lukewarm, however continued enchancment in demand, and progress with vaccine improvement buoyed market sentiment
As the worldwide financial system opens up and lockdowns are lifted in phases, shopper demand is predicted to select up. This could possibly be mirrored within the type of a pick-up in elective surgical procedures and whole revenues towards the top of 2020, adopted by continued income progress in 2021, boding effectively for BIIB inventory within the close to time period. Whereas we imagine that BIIB inventory may rally again to its pre-Covid ranges of $340, implying over 35% upside from the present ranges, the beneficial properties can be a lot larger if Aducanumab sees a inexperienced mild from the U.S. FDA.
What for those who’re searching for a extra balanced portfolio as a substitute? Right here’s a high-quality portfolio to beat the market, with over 100% return since 2016, versus 55% for the S&P 500. Comprised of firms with robust income progress, wholesome earnings, lots of money, and low danger, it has outperformed the broader market yr after yr, constantly.
See all Trefis Value Estimates and Obtain Trefis Information right here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Groups | Product, R&D, and Advertising and marketing Groups
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.